• EyeGate® II Delivery System
• Our Strategy
• Management
• Board of Directors
• Scientific Advisory Board

Our Strategy

EyeGate Pharma is focused on replacing ocular injections and other invasive methods of ocular disease treatment. Our goal is to build a pipeline of safer, more effective and patient friendly ocular treatments based on our EyeGate® II Delivery System. Our initial focus will be on developing a product for the treatment of the inflammatory condition uveitis - a product combination using a corticosteroid and the EyeGate® II Delivery System. Additional indications and product pipeline opportunities are expected to follow shortly.

The company will not embark upon expensive and risky early-stage drug discovery. However, we see the important contribution that the technology platform could have to other companies with unique and proprietary medicines. As such, we will actively embrace discussions for out-licensing our product platform to more effectively bring new medicines to those in most need.